BioCentury
ARTICLE | Company News

Gilead ends GlobeImmune HBV deal

November 18, 2016 10:48 PM UTC

GlobeImmune Inc. (Pink:GMIB) said Gilead Sciences Inc. (NASDAQ:GILD) returned rights to HBV candidate GS-4774 and terminated a 2011 partnership to develop HBV vaccines. The companies had hoped to create vaccines based on GlobeImmune's Tarmogen products, which are whole, heat-killed, recombinant Saccharomyces cerevisiae genetically modified to express a disease-associated antigen (see BioCentury Extra, Oct. 24, 2011).

GlobeImmune also said President and CEO Timothy Rodell resigned, and that it terminated the lease for its corporate headquarters. GlobeImmune was delisted from NASDAQ in July...